- Home
- GNLX
GNLX
Genelux Corporation
as 07-26-2024 4:00pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 74.5M | IPO Year: | 2023 |
| Target Price: | $32.33 | AVG Volume (30 days): | 320.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.71 - $30.44 | Next Earning Date: | 08-12-2024 |
| Revenue: | $8,000 | Revenue Growth: | -99.93% |
| Revenue Growth (this year): | -96.4% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Genelux Corporation (GNLX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Szalay Aladar | GNLX | 10% Owner | May 13 '24 | Sell | $3.66 | 17,094 | $62,623.87 | 1,139,821 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | May 13 '24 | Sell | $3.58 | 15,426 | $55,274.44 | 1,156,915 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | May 13 '24 | Sell | $3.62 | 3,446 | $12,478.31 | 1,172,341 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | May 7 '24 | Sell | $3.67 | 6,025 | $22,111.15 | 1,189,706 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | May 7 '24 | Sell | $3.82 | 13,919 | $53,188.67 | 1,175,787 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 29 '24 | Sell | $3.30 | 33,061 | $109,160.81 | 1,195,731 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 29 '24 | Sell | $3.12 | 20,535 | $63,980.90 | 1,228,792 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 29 '24 | Sell | $3.25 | 6,403 | $20,792.46 | 1,249,327 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 22 '24 | Sell | $3.53 | 14,331 | $50,597.03 | 1,285,794 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 22 '24 | Sell | $3.49 | 22,000 | $76,799.80 | 1,263,794 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 22 '24 | Sell | $3.50 | 8,064 | $28,250.61 | 1,255,730 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 16 '24 | Sell | $3.53 | 48,683 | $171,802.31 | 1,322,862 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Apr 16 '24 | Sell | $3.71 | 22,737 | $84,424.75 | 1,300,125 | SEC Form 4 |
| Jewett Caroline | GNLX | Head of Quality | Feb 19 '24 | Sell | $2.12 | 4,961 | $10,517.32 | 16,174 | SEC Form 4 |
| Ryder Sean | GNLX | General Counsel | Feb 19 '24 | Sell | $2.12 | 5,496 | $11,651.52 | 19,388 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Dec 15 '23 | Sell | $12.94 | 26,732 | $345,914.75 | 5,803 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Dec 15 '23 | Sell | $14.18 | 5,803 | $82,265.07 | 0 | SEC Form 4 |
| Tyree James L | GNLX | Director | Dec 13 '23 | Sell | $12.91 | 5,653 | $73,005.67 | 6,807 | SEC Form 4 |
| Tyree James L | GNLX | Director | Dec 13 '23 | Sell | $13.73 | 3,347 | $45,963.35 | 3,460 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Dec 7 '23 | Sell | $11.85 | 36,800 | $435,995.36 | 32,535 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Nov 17 '23 | Sell | $13.04 | 3,541 | $46,169.68 | 102,594 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Nov 17 '23 | Sell | $11.26 | 14,594 | $164,261.31 | 88,000 | SEC Form 4 |
| Yu Yong | GNLX | VP, Clinical Trial Operations | Oct 24 '23 | Sell | $19.11 | 5,200 | $99,351.20 | 106,135 | SEC Form 4 |
| Szalay Aladar | GNLX | 10% Owner | Oct 23 '23 | Sell | $19.97 | 49,987 | $998,365.36 | 1,377,249 | SEC Form 4 |
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Top Midday Decliners
MT Newswires
2 months ago
Genelux Prices $27.5 Million Securities Offering at $4 a Share; Shares Drop
GlobeNewswire
2 months ago
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
MT Newswires
2 months ago
Genelux Launches Securities Offering; Shares Fall After-Hours
GlobeNewswire
2 months ago
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
MT Newswires
2 months ago
Top Premarket Gainers
GlobeNewswire
3 months ago
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Simply Wall St.
3 months ago
Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
Compare GNLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.